Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss

Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.